France is making an attempt to catch up in biomedicines | EUROtoday

Get real time updates directly on you device, subscribe now.

Researchers from the National Institute of Health and Medical Research, in October 2021, in Strasbourg.

Vaccines, monoclonal antibodies, gene or cell therapies, antibiotics, and many others. Biomedicines, these merchandise whose lively substances come from dwelling organisms (cells of animal or human origin, microorganisms), and that are distinguished from medicines obtained by chemical synthesis, are booming. Capable of appearing on particular targets, these cutting-edge remedies have already made it attainable to enhance the prognoses of sure cancers in recent times, and even to treatment uncommon illnesses. But France missed the shift to those improvements a number of years in the past and has since struggled to meet up with the amassed delay.

Read additionally | Article reserved for our subscribers In Alès, LFB doubles its manufacturing of biomedicines

France produced solely eight on nationwide soil in 2022 out of the seventy-six approved for advertising and marketing in Europe, particularly thanks to 2 French firms, Sanofi and the general public laboratory LFB, in addition to the Swiss Novartis. However, the difficulty is much from negligible: 59% of medicine presently in growth worldwide concern biotherapies.

“In 2020, international gross sales had been price $300 billion [280 milliards d’euros] in a drug market valued at greater than $1.1 trillion. And projections point out that they are going to weigh double in 2030. This is a big progress driver for the pharmaceutical trade », observes Laurent Lafferrère, basic director of France Biolead, which brings collectively gamers within the sector in France. Not to say the difficulty of nationwide sovereignty: 95% of biomedicines consumed in France are at present imported.

Promote synergies

Launched below the impetus of the State, in December 2022, the affiliation, which brings collectively below its banner greater than fifty members who intervene in all hyperlinks within the biomedicine chain, from analysis to manufacturing, Since its creation, it has been striving to construction the sector, which till now has been shifting in a dispersed method. With one goal: to make France a future European champion.

For eighteen months, it has labored, amongst different issues, to checklist the totally different gamers within the ecosystem in France to make the sector extra comprehensible and promote synergies, and is getting ready, on July 5, to inaugurate a nationwide day meant to advertise, all through France, the sector to most people. Because the sector, in full growth, is recruiting. It goals to double its workforce by 2030, to succeed in 20,000 jobs.

Also learn the decryption: Article reserved for our subscribers In the battle between biosimilars and biomedicines, the Ministry of Health seeks a consensus

At the identical time, the affiliation has launched work to determine the responses to the main challenges of the sector, notably when it comes to regulatory simplification to encourage the competitiveness of the French trade, or on technological improvements in manufacturing processes. . “We should be sure that these biomedicines, that are very costly at present, may have a sustainable price for our well being system. This requires enhancing yields to supply extra, higher and at decrease price. », explains Mr. Lafferrère. France Biolead is working to arrange consortia to pool the efforts of producers.

You have 40% of this text left to learn. The relaxation is reserved for subscribers.

https://www.lemonde.fr/economie/article/2024/06/27/la-france-tente-de-combler-son-retard-dans-les-biomedicaments_6244581_3234.html